Publication | Open Access
Prevalence and Knowledge of Potential Interactions Between Over‐the‐Counter Products and Apixaban
26
Citations
27
References
2019
Year
Significant numbers of patients take OTC products (particularly dietary supplements) with potentially serious interactions with the DOAC apixaban and appear to lack knowledge about potentially harmful interactions. Interventions are needed to educate patients and healthcare providers about potential dangers of taking interacting OTC products in combination with apixaban, and data are needed on outcomes associated with concomitant apixaban-OTC product use. J Am Geriatr Soc 68:155-162, 2019.
| Year | Citations | |
|---|---|---|
Page 1
Page 1